Prostate Cancer Drug Futures

Report Summary

AN EXCEPTIONALLY COST EFFECTIVE SERVICE INCLUDING FORMATS TO MEET EVERY INFORMATION NEED
Espicom's Prostate Cancer Drug Futures includes formats to meet differing information requirement of customers. For constant vigilance and up-to-date coverage of lung cancer drug development users can access the 24/7 daily updated web service. For strategic periodic reviews we also provide quarterly-updated reports of all drugs in a convenient pdf document. All for one cost-effective annual price of £1,495/US$2,615/€1,865

• 24/7 web access
• Quarterly updated pdf reports
• Single cost-effective price
• All updates including any new drugs added during your license period
• Related news
• Espicom’s research methodology for forecasting and including an explanation of the competitor ratio analysis scoring system.

The prostate cancer (PC) market is on the verge of considerable change....

with the imminent arrival of new targeted therapies that will prolong patient survival. PC is the second leading cause of new cancer cases in men worldwide and the sixth leading cause of cancer death in men. In the US, over two million men currently suffer with PC and it is estimated that there were 192,311 new cases and 29,698 deaths due to the disease in 2008. There have been dramatic improvements in PC survival over the last 25 years, mainly due to a combination of earlier diagnosis and improvements in treatments, although rates vary between countries

The PC market was estimated to be worth US$5.2 billion in 2008; it is one of the larger segments of the oncology market, alongside breast, non-small cell lung and colorectal cancers. The market is currently driven by the use of hormonal therapies, which are prescribed mainly for advanced hormone-dependent PC. However, the market dynamics will change considerably over the next six years as patents expire and generic competition intensifies. Research into new therapies is extremely active and new agents with novel modes of action are being evaluated.

NOW YOU CAN STAY IN TOUCH WITH THE DEVELOPMENTS WHICH MATTER
This all new web service from Espicom, Prostate Cancer Drug Futures, assesses the future prospects for market success for individual drugs. Based on independent research and proprietary analysis, each product assessed brings the prospects for a product into clear focus. Best of all, each drug is regularly reviewed ensuring that latest developments are incorporated for you to see.

WITH EACH KEY DRUG ANALYSED IN THIS SERVICE YOU CAN...

Track the drug’s progress and stay abreast of developments
Understand the drug’s novelty and mode of action
Evaluate the strength of the company developing/producing the drug
Review opportunities and challenges with Espicom’s unique 5-point competitive assessment
Know the launch timeframe for new products or indications
Be aware of promising mid-stage development candidates
Estimate future revenues with original 5-year forecasts for launched and leading pipeline candidates
Review significant clinical trial results

STRUCTURED ANALYSIS OF KEY DRIVERS AND DAMPENERS OF SUCCESS

For each product analysed there is an extensive and standardised review of the factors which can affect its clinical and commercial performance. Those factors include…

Novelty/rationale for mechanism of action
Current status
Proof of concept/clinical data
Development risks
Company expertise
Competition within the market-place
Sales forecast (for key late-stage and launched products)
Competitor ratio analysis score
Clinical trial results

OVER 45 PROSTATE DRUGS INCLUDE:
Because this service is continually updated, products will be added, deleted or enhanced in response to ongoing developments throughout the course of your licence. From time-to-time drug profiles may be removed from the service for essential updating.

Approved
Bicalutamide
Cabazitaxel
Degarelix
Docetaxel
Goserelin
Leuprorelin
Mitoxantrone
Paclitaxel
Sipuleucel-T
 Filed
Dutasteride
 Phase III
Abiraterone acetate
Aflibercept
Dasatinib
Ipilimumab
Radium-223
ZD4054
 Phase II
AT-101
Bortezomib
Cixutumumab
E75 GM-CSF adjuvant vaccine
Enzastaurin
Figitumumab
Ixabepilone
OGX-011
OnyVax-P
PROSTVAC
Ramucirumab
Sagopilone
Vadimezan
 
CLEAR, CONCISE, AND ORIGINAL ANALYSIS GIVES YOU KEY PRODUCT INSIGHTS

Espicom's Cancer Drug Futures incorporate the latest analysis from our in-house team of life scientists and statisticians across a range of cancer areas. Their research builds upon Espicom's established knowledge base of up-to-date intelligence on thousands of pharmaceutical manufacturers and research companies, backed up by a fifteen years’ of archive material.

Taking all aspects of the market into account, from clinical trials, deals and alliances to company financial performance and drug sales, the analysis and forecasting that contributes to Espicom's Cancer Drug Futures is standardised across each individual launched product or drug candidate and is founded upon a diligent and thorough research process.

With Espicom’s Cancer Drug Futures you can easily evaluate the prospects of the drugs of interest to you and discover its progress in each indication. Each report provides individual and highly-detailed analysis of the drug, looking at the key factors affecting its future performance in the marketplace.

BUILD YOUR OWN DRUG FUTURES LIBRARY WITH 4D RESEARCH!

4D Research is Espicom’s tailored information service. Using 4D Research, customers can build their own Futures library of individual drugs of interest. Indeed, the service can include any of Espicom’s leading information services. Attractive discounts are available to buyers of multiple Futures and our cost-effective distribution license means these key data can be shared with colleagues.
 

Table Of Contents

Overview
Phase I
Ae37
Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis

Asp0265
Current Status

Sar109659
Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Clinical Trial Results

Phase I/Ii
Bortezomib
Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Data Exclusivity
Patent Expiry
Generic Competition
Competitor Ratio Analysis
Forecast
Clinical Trial Results

Phase Ii
at-101
Mode of Action
Current Status
Proof of Concept
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast

Cixutumumab
Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis

Custirsen Sodium
Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis

Degarelix
Mode of Action
Current Status
Proof of Concept
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast

Dovitinib
Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise

E75 Gm-Csf Adjuvant Vaccine
Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast

Enzastaurin
Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast
Clinical Trial Results

Erbulin
Clinical Trial Results

Figitumumab
Mode of Action
Current Status
Proof of Concept
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Clinical Trial Results

Ixabepilone
Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast
Clinical Trial Results

Ly2181308
Mode of Action
Current Status
Proof of Concept/Clinical Data

Onyvax-P
Mode of Action
Current Status
Proof of Concept
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast

Prostvac
Mode of Action
Current Status
Proof of Concept
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast

Ramucirumab
Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast

Sagopilone
Mode of Action
Current Status
Proof of Concept/Clinical Data
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Clinical Trial Results

Tasq
Mode of Action
Current Status
Proof of Concept
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast

Vadimezan
Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast
Source: Espicom.
Clinical Trial Results

Phase Iii
Abiraterone Acetate
Mode of Action
Current Status
Proof of Concept
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast

Aflibercept
Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast
Clinical Trial Results

Dasatinib
Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast
Clinical Trial Results

Dutasteride
Mode of Action
Sales
Current Status
Proof of Concept
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast
Clinical Trial Results

Gvax
Clinical Trial Results
Monotherapy
Combination with Ipilimumab

Ipilimumab
Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast
Clinical Trial Results

Mdv3100
Mode of Action
Current Status
Proof of Concept
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast

Picoplatin
Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Patent Expiry
Competitor Ratio Analysis

Radium-223
Mode of Action
Current Status
Clinical Trial Results

Sunitinib Malate
Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Data Exclusivity
Patent Expiry
Generic Competition
Competitor Ratio Analysis
Forecast
Clinical Trial Results

Toremifene
Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis

Trabectedin
Mode of Action
Current Status
Further Development
Clinical Trial Results

Zd4054
Mode of Action
Current Status
Proof of Concept
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast
Clinical Trial Results

Filed
Cabazitaxel
Mode of Action
Current Status
Proof of Concept
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast
Clinical Trial Results

Satraplatin
Mode of Action
Current Status
Proof of Concept
Development Risks
Company Expertise
Competitor Ratio Analysis
Forecast

Approved
Bicalutamide
Mode of Action
Current Status
Proof of Concept
Development Risks
Company Expertise
Competition within the Market-place
Generic Competition
Competitor Ratio Analysis
Forecast

Cyproterone Acetate
Mode of Action
Current Status

Docetaxel
Mode of Action
Sales
Current Status
Proof of Concept
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast
Clinical Trial Results

Goserelin
Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Patent Expiry
Generic Competition
Competitor Ratio Analysis
Forecast

Leuprorelin
Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Patent Expiry
Generic Competition
Competitor Ratio Analysis
Forecast

Mitoxantrone
Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Patent Expiry
Generic Competition
Clinical Trial Results

Sipuleucel-T
Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast
Clinical Trial Results

Withdrawn
Bevacizumab
Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast
Clinical Trial Results

Saracatinib
Mode of Action

Methodology